While it’s certainly interesting to theorize about neurotransmitters and antidepressants, the recent STAR*D findings bring up a difficult topic: Does mechanism matter?
Read More
Dopamine is the new serotonin: everyone is talking about it. Depending on what authority you read, dopamine is central to schizophrenia, ADHD, depression, sexuality, and cognition.
Read More
Anticholinergic-speak is endemic in psychiatry. Since it’s unlikely to go away, we invite you to buff up your knowledge of acetylcholine (ACh) and to review the many ways in which it makes an appearance in clinical practice.
Read More
Dr. Barondes, you were a researcher at the NIH during the period when the earliest research on neurotransmitters and antidepressants was conducted. What happened while you were there?
Read More
Julius Axelrod, who won the Nobel Prize for his work in neuroscience, spent much of his career as a lab tech. Born in 1912 on the Lower East Side of Manhattan, he got most of his education at the tuition-free City College of New York, which he described as a “proletarian Harvard.”
Read More
Dr. Aiken is the Editor in Chief of The Carlat Psychiatry Report; director of the Mood Treatment Center in North Carolina, where he maintains a private practice combining medication and therapy along with evidence-based complementary and alternative treatments; and Assistant Professor NYU Langone Department of Psychiatry. He has worked as a research assistant at the NIMH and a sub-investigator on clinical trials, and conducts research on a shoestring budget out of his private practice. Follow him on Twitter and find him on LinkedIn.
_-The-Breakthrough-Antipsychotic-That-Could-Change-Everything.jpg?1729528747 "KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg")
